Lexicon Pharmaceuticals Statistics
Lexicon Pharmaceuticals (LX31) Stock Statistics & Valuation Metrics
Total Valuation
Lexicon Pharmaceuticals has a market cap or net worth of EUR 722.97M. The enterprise value is EUR 710.63M.
- Market Cap
- EUR 722.97M
- Enterprise Value
- EUR 710.63M
Share Statistics
Lexicon Pharmaceuticals has 445,234,560 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 445,234,560
- Owned by Insiders
- 61.21%
- Owned by Institutions
- 19.13%
Financial Efficiency
Lexicon Pharmaceuticals’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -28.71%.
- Return on Equity (ROE)
- -0.47
- Return on Assets (ROA)
- -0.27
- Return on Invested Capital (ROIC)
- -28.71%
- Return on Capital Employed (ROCE)
- -0.30
- Revenue Per Employee
- 614.85K
- Profits Per Employee
- -621.49K
- Employee Count
- 81
- Asset Turnover
- 0.27
- Inventory Turnover
- 0.98
Valuation Ratios
The current PE Ratio of Lexicon Pharmaceuticals is -12.32. Lexicon Pharmaceuticals’s PEG ratio is 0.10.
- PE Ratio
- -12.32
- PS Ratio
- 20.68
- PB Ratio
- 4.86
- Price to FCF
- -12.46
- Price to Operating Cash Flow
- -12.45
- PEG Ratio
- 0.10
Income Statement
In the last 12 months, Lexicon Pharmaceuticals had revenue of 49.80M and earned -50.34M in profits. Earnings per share was -0.14.
- Revenue
- 49.80M
- Gross Profit
- 49.53M
- Operating Income
- -48.91M
- Pretax Income
- -50.34M
- Net Income
- -50.34M
- EBITDA
- -41.38M
- Earnings Per Share (EPS)
- -0.14
Cash Flow
In the last 12 months, operating cash flow was -63.96M and capital expenditures 0, giving a free cash flow of -63.96M billion.
- Operating Cash Flow
- -63.96M
- Free Cash Flow
- -63.96M
- Free Cash Flow per Share
- -0.14
Dividends & Yields
Lexicon Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -8.03%
- Earnings Yield
- -7.83%
Stock Price Statistics
- Beta
- 1.44
- 52-Week Price Change
- -19.44%
- 50-Day Moving Average
- 1.01
- 200-Day Moving Average
- 1.01
- Relative Strength Index (RSI)
- 36.49
- Average Volume (3m)
- ―
Important Dates
Lexicon Pharmaceuticals upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Lexicon Pharmaceuticals as a current ratio of 4.88, with Debt / Equity ratio of 57.87%
- Current Ratio
- 4.88
- Quick Ratio
- 4.87
- Debt to Market Cap
- 0.13
- Net Debt to EBITDA
- -0.67
- Interest Coverage Ratio
- -5.87
Taxes
In the past 12 months, Lexicon Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Lexicon Pharmaceuticals EV to EBITDA ratio is -14.46, with an EV/FCF ratio of -12.70.
- EV to Sales
- 21.08
- EV to EBITDA
- -14.46
- EV to Free Cash Flow
- -12.70
- EV to Operating Cash Flow
- -12.70
Balance Sheet
Lexicon Pharmaceuticals has EUR 183.20M in cash and marketable securities with EUR 59.54M in debt, giving a net cash position of EUR 123.67M billion.
- Cash & Marketable Securities
- EUR 183.20M
- Total Debt
- EUR 59.54M
- Net Cash
- EUR 123.67M
- Net Cash Per Share
- EUR 0.28
- Tangible Book Value Per Share
- EUR 0.27
Margins
Gross margin is 98.59%, with operating margin of -147.42%, and net profit margin of -161.80%.
- Gross Margin
- 98.59%
- Operating Margin
- -147.42%
- Pretax Margin
- -161.80%
- Net Profit Margin
- -161.80%
- EBITDA Margin
- -145.80%
- EBIT Margin
- -146.91%
Analyst Forecast
The average price target for Lexicon Pharmaceuticals is EUR 5.21, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 5.21
- Price Target Upside
- 417.63% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 10
- AI Score
- ―

